Drug intelligence / Profile preview

JNJ-42491293

Development stage: Unknown
Lead developer: Janssen Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

JNJ-42491293 is a potent, selective positive allosteric modulator (PAM) and ago-PAM (allosteric agonist/positive allosteric modulator) of the metabotropic glutamate receptor 2 (mGlu2). It was developed as a radiolabeled PET tracer for imaging mGlu2 receptor availability in the brain. The compound binds to an allosteric site on mGlu2 with high affinity and selectivity, showing reversible kinetics and no significant off-target activity. Its primary use has been in preclinical and clinical research to study mGlu2 distribution, function, and occupancy in neuropsychiatric disorders such as anxiety, schizophrenia, and addiction. JNJ-42491293 was developed by Janssen (a Johnson & Johnson company)[1][4][5][6].

Targets

GRM2 (mGluR2)

Beyond the preview

Go deeper on JNJ-42491293.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-42491293.

Explore the full profile